AN2 Therapeutics, Inc.
ANTXHealthcare|Biotechnology|US
$4.00
+0.04 (+1.14%)
DCF Value
$0.59
Tangible Book / Share
$1.70
Cash / Share
$1.75
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07301320 Epetraborole in Patients With Mycobacterium Abscessus Lung Disease | Mycobacterium Abscessus Infection | P2 | Recruiting | 84 | RCT, Double-blind | Epetraborole, Epetraborole, Placebo, Placebo |
| NCT05327803 Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease | MAC Lung Disease, Treatment Refractory MAC Lung Disease | P2P3 | Terminated | 177 | RCT, Double-blind | Epetraborole, Placebo |
| NCT07891533 Phase 2 Study of Oral Epetraborole in Adults With Polycythemia Vera | Polycythemia Vera (SNOMED CT: 109992005) | P2 | Not Yet Recruiting | 75 | RCT, Double-blind | Epetraborole, Placebo |
| NCT05283746 A Study of Epetraborole Tablets in Subjects With Degrees of Renal Function | Renal Insufficiency | P1 | Completed | 40 | Open-label | Epetraborole |
| NCT07024589 First-in-Human Trial of Oral AN2-502998 | Healthy Volunteers | P1 | Completed | 72 | RCT, Double-blind | AN2-502998, Placebo |
| NCT05995444 A Study to Assess the Effects of Epetraborole on the QT Interval in Healthy Adult Subjects | Healthy Volunteers | P1 | Completed | 24 | RCT, Double-blind | Epetraborole and matching placebo, Epetraborole, Placebo, Moxifloxacin |
| NCT04892641 Phase 1 Study of Epetraborole Tablets | Healthy Volunteers | P1 | Completed | 51 | RCT, Double-blind | Epetraborole, Placebo |
| NCT06089668 An Observational Study to Evaluate Clinical Characteristics of Adult Patients With Suspected or Confirmed Melioidosis | Melioidosis | Completed | 200 | — | — |